Pretreatment ¹⁸F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer

Table 4

Multivariate analysis of the KRAS/NRAS/BRAF status in patients with CRC (n = 85).

Factors	OR (95% CI)
Age	0.98 (0.95–1.02)	0.420
BMI	1.03 (0.89–1.20)	0.664
Tumor location	2.06 (0.63–6.67)	0.231
SUVmax	1.08 (1.01–1.16)	0.028
Age	0.98 (0.94–1.02)	0.402
BMI	1.04 (0.89–1.22)	0.578
Tumor location	2.19 (0.66–7.33)	0.203
T/NT	1.25 (1.05–1.49)	0.012

OR: odds ratio; CI: confidence interval; BMI: body mass index; SUVmax: maximum standardized uptake value; T/NT: target lesion to nontarget lesion ratio.